Piśmiennictwo:
1. Beusterien KM, Rogers AE, Walsleben JA, et al. Health-related quality of life effects of modafinil for treatment of narcolepsy. Sleep 1999;22:757-65.
2. Dodel R, Peter H, Walbert T, et al. The socioeconomic impact of narcolepsy. Sleep 2004;27:1123-8.
3 Morrish E, King MA, Smith IE, et al. Factors associated with a delay in the diagnosis of narcolepsy. Sleep Med 2004;5:37-41.
4. Ohayon MM, Priest RG, Zulley J, et al. Prevalence of narcolepsy symptomatology and diagnosis in the European general population. Neurology 2002;58:1826-33.
5. Stores G, Crawford C. Medical student education in sleep and its disorders. J R Coll Physicians Lond 1998;32:149-53.
6. Breslau N, Roth T, Rosenthal L, et al. Daytime sleepiness: an epidemiological study of young adults. Am J Pub Health 1997;87:1649-53.
7. Littner MR, Kushida C, Wise M, et al. Practice parameters for clinical use of the multiple sleep latency test and the maintenance of wakefulness test. Sleep 2005;28:113-21.
8. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991;14:540-5.
9. American Academy of Sleep Medicine. Diagnostic and coding manual. International classification of sleep disorders, 2nd edn. Westchester, IL:AASM, 2005.
10. Aldrich M. Narcolepsy and related disorders. In: Aldrich M, Sleep medicine. New York: Oxford University Press, 1999:152-74.
11. Parkes JD, Chen SY, Clift SJ, et al. The clinical diagnosis of the narcoleptic syndrome. J Sleep Res 1998;7:41-52.
12. Scammell TE. The neurobiology, diagnosis, and treatment of narcolepsy. Ann Neurol 2003;53:154-66.
13. Zeman A, Britton T, Douglas N, et al. Narcolepsy and excessive daytime sleepiness. BMJ 2004;329:724-8.
14. Mignot E, Lammers GJ, Ripley B, et al.The role of cerebrospinal fluid hypocretin mea-surement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 2002;59:1553-62.
15. Peyron C, Faraco J, Rogers W, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000;6:991-7.
16. Thannickal TC, Moore RY, Nienhuis R, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000;27:469-74.
17. Mignot E. Genetic and familial aspects of narcolepsy. Neurology 1998;50(2 Suppl 1):S16-22.
18. Lin L, Hungs M, Mignot E. Narcolepsy and the HLA region. J Neuroimmunol 2001;117:9-20.
19. Hallmayer J, Faraco J, Lin L, et al. Narcolepsy is strongly associated with the T-cell receptor alpha locus. Nat Genet 2009;41:708-11.
20. Aran A, Lin L, Nevsimalova S, et al. Elevated anti-streptococcal antibodies in patients with recent narcolepsy onset. Sleep 2009;32:979-83.
21. MS, Chervin RD, Malow BA. Value of the multiple sleep latency test (MSLT) for the diagnosis of narcolepsy. Sleep 1997;20:620-9.
22. Mignot E, Lin L, Finn L, et al. Correlates of sleep-onset REM periods during the Multiple Sleep Latency Test in community adults. Brain 2006;129:1609-23.
23. Morgenthaler TI, Kapur VK, Brown T, et al. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep 2007;30:1705-11.
24. Ali M, Auger RR, Slocumb NL, et al. Idiopathic hypersomnia: clinical features and response to treatment. J Clin Sleep Med 2009;5:562-8.
25. Mitler M, Aldrich MS, Koob GF, et al. Narcolepsy and its treatment with stimulants. ASDA standards of practice. Sleep 1994;17:352-71.